3 Obesity Drug Stocks to Buy ASAP

The drug treatment boom is taking off The drug treatment boom is taking off                                                                                                      [Morning Watchlist] You are receiving this email because you are subscribed to Behind the Markets. If you no longer wish to receive these emails, please [unsubscribe]( here. Prefer to view this content on our website? [Click here.]( --------------------------------------------------------------- Dear Fellow Investor, New obesity figures were recently announced. And they’re not so good. According to the World Health Organization, obesity has more than doubled since 1990. In fact, global adult obesity has more than doubled since 1990, and adolescent obesity has quadrupled. And over 390 million children and adolescents aged five to 19 years were overweight in 2022, including 160 million who were living with obesity. While that’s not great for millions of obese people around the world, it’s great news for biotech stocks getting caught up in the drug treatment boom. --------------------------------------------------------------- Company: Eli Lilly (SYM: LLY) Just look at Eli Lilly (SYM: LLY). The company is seeing so much demand it’s spending $5.3 billion to make even more Mounjaro and Zepbound. According to The Wall Street Journal, Zepbound alone is generating more than 78,000 prescriptions every week in the U.S. No wonder shares of LLY exploded from a January low of about $580 to $901.26. --------------------------------------------------------------- Financial Markets Daily [Little-known biotech company just had groundbreaking results from a study]( [biotech]( As biotech stages a big comeback, one NYSE-traded company looks well-positioned to be a market disruptor with nontoxic, effective antiviral therapies based on patented nanomedicine technology. [>> Get the stock symbol here <<]( --------------------------------------------------------------- Other top stocks to keep an eye on include: Company: Viking Therapeutics (SYM: VKTX) The company reported that the injectable form of its treatment helped patients lose up to 13.1% of their weight after 13 weeks in Phase 2 trials. Then, the company said the tablet form of its treatment led to a weight loss of about 3.3% after 28 days in Phase 1 trials. Two, thanks to Viking’s success in obesity drug trials, analysts at BTIG just reiterated a buy rating with a price target of $125 a share. --------------------------------------------------------------- Oxford Club [AI's Next Magnificent Seven]( [chart](The Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years. $1,000 in each turned into $1.18 million! But the Man Who Called Nvidia at $1.10 Says "AI"s Next Magnificent Seven Could Do It Even Faster." He says $1,000 in these seven stocks could turn into $1 million+ in less than six years. [See His Breakdown of the Seven Stocks You Should Own Here.]( --------------------------------------------------------------- Company: Altimmune (SYM: ALT) Recent Phase 2 results showed that patients lost an average of 15.6% of their body weight at 48 weeks at the highest dose. The study also found that the treatment led to better lean mass preservation as compared to other similar weight loss treatments. "Preservation of lean mass, which is primarily muscle tissue, is believed to be important in maintaining healthy weight loss and physical function," CEO Vipin Garg said in a news release. "We believe that the level of muscle preservation observed in the Phase 2 trial further adds to the differentiation of pemvidutide in the treatment of obesity." --------------------------------------------------------------- Goldencrest Metals [Biden’s 44.6% Tax Bombshell: Protect Your Savings Now]( Leading economists are issuing stark warnings: The anticipated capital gains tax increase under President Biden could drastically undermine your retirement plans by 2025. [Click here to unlock your exclusive guide before it's too late.]( --------------------------------------------------------------- [Join Daily Guru Trades!]( Want more free daily trades in your inbox? [Sign up for Dylan Jovine's Daily Guru Trades Today.]( Do you own any shares of obesity drug companies? Do you have your eye on any under-the-radar obesity treatment stocks that we might have missed? Hit "reply" to this email and let us know! Our mailing address is: Behind the Markets, LLC 4260 NW 1st Avenue, Suite 55 Boca Raton, FL 33431 Copyright © 2024 Behind the Markets, LLC, All rights reserved. You're receiving this email as part of your subscription to Behind the Markets. For more information about our privacy practices, please review our [Privacy Policy]( or our [Legal Notices.]( We are issuing this disclosure in compliance with Section 17(b) of the Securities Act, which requires us to disclose any compensation received or expected to be received in cash or in kind in connection with the purchase or sale of any security. We would like to inform you that we have received or expect to receive compensation in connection with the purchase or sale of the securities of NanoViricides, Inc. (NYSE American: NNVC). The compensation consists of up to $3,000 and was received/will be received from Interactive Offers. This compensation should not be considered as an endorsement of the securities of adviser NanoViricides, Inc. (NYSE American: NNVC) and we are not responsible for any errors or omissions in any information provided about the securities of NanoViricides, Inc. (NYSE American: NNVC) and Financial Markets Daily. We encourage you to conduct your own due diligence and research before making any investment decisions. You should also consult with a financial advisor before making any investment decisions. This disclosure is made as of 6/28/24. [Behind the Markets]( [Unsubscribe](